Drug Trial Radar · NCT07801612
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Oct 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Helixon Biotechnology (Suzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD). The study consists of two parts: Part A (single ascending dose in healthy participants) and Part B (multiple ascending dose in AD patients). The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary efficacy of HXN5003.
Conditions
- Health Adult Subjects
- Moderate-to-Severe Atopic Dermatitis
Interventions
HXN5003Drug
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of HXN5003.
PlaceboDrug
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of placebo.
HXN5003Drug
AD participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of HXN5003.
PlaceboDrug
AD Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Adverse eventsTime frame: Up to day 197
- Part B Adverse EventsTime frame: Up to day 281
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.